{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:34:06Z","timestamp":1774614846225,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Understanding the natural history of chronic hepatitis B (CHB) virus infection is important for determining optimal management and predicting prognosis in patients. The aim of this study was to determine the prevalence of different phases of CHB infection among Eritrean patients and to identify the proportion of patients who are eligible for treatment according to the latest American Association for the Study of Liver Diseases (AASLD) guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional study enrolled 293 CHB patients (213 males and 80 females) between Jan 2017 and Feb 2019. The patients were classified into immune-tolerant, immune-active, and inactive CHB phases of the infection, which is based on the results of Hepatitis B virus (HBV) serological panel (HBsAg, anti-HBc total, HBeAg, and anti-HBe), ALT levels, and HBV DNA viral load. The 2018 AASLD guidelines were also used to identify patients who needed treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The mean age of the patients was 41.66\u2009\u00b1\u200913.84\u00a0years. Of these, 3 (1.0%) were at the immune tolerant phase, 58 (19.8%) at the immune-active CHB phase, and 232 (79.2%) at the inactive CHB phase. As most subjects (93%) were HBeAg-negative, based on AASLD guidelines, only 5 (1.7%) were currently eligible for treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our data show that CHB patients in Eritrea were predominantly in the inactive CHB phase. Although initiating antiviral therapy is not recommended in these patients, periodic assessment of liver function and disease severity should be considered in patients older than 40\u00a0years<jats:bold>.<\/jats:bold> The immune-tolerant phase had the fewest patients, most of whom were aged above 20\u00a0years, attesting to the success of incorporating HBV vaccine in the national childhood immunization program since 2002. Our study shows that adopting AASLD treatment guidelines with adjustments to suit the local setting is a suitable option in the management of Eritrean CHB patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-021-01789-3","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:08:01Z","timestamp":1620043681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of chronic hepatitis B phases in Eritrean patients: a laboratory-based cross-sectional study"],"prefix":"10.1186","volume":"21","author":[{"given":"Mohammed Elfatih","family":"Hamida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saud Mohammed","family":"Raja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yemane","family":"Seyoum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isam Mohammed","family":"Elkhidir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freweini","family":"Tekle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"key":"1789_CR1","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v9040075","volume":"9","author":"T Tu","year":"2017","unstructured":"Tu T, Budzinska MA, Shackel NA, Urban S. HBV DNA integration: molecular mechanisms and clinical implications. Viruses. 2017;9:75.","journal-title":"Viruses"},{"key":"1789_CR2","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, Mcmahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560\u201399.","journal-title":"Hepatology"},{"key":"1789_CR3","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","volume":"388","author":"JD Stanaway","year":"2016","unstructured":"Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet. 2016;388:1081\u20138.","journal-title":"Lancet"},{"key":"1789_CR4","doi-asserted-by":"publisher","first-page":"10395","DOI":"10.3748\/wjg.v20.i30.10395","volume":"20","author":"CM Croagh","year":"2014","unstructured":"Croagh CM, Lubel JS. Natural history of chronic hepatitis B: phases in a complex relationship. World J Gastroenterol. 2014;20:10395\u2013404.","journal-title":"World J Gastroenterol"},{"key":"1789_CR5","first-page":"990","volume":"43","author":"Z Sharifi","year":"2014","unstructured":"Sharifi Z. Natural history of chronic hepatitis B virus infection based on laboratory testing. Iran J Public Health. 2014;43:990\u20133.","journal-title":"Iran J Public Health"},{"key":"1789_CR6","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/occmed\/kqr136","volume":"61","author":"EJ Aspinall","year":"2011","unstructured":"Aspinall EJ, Hawkins G, Fraser A, Hutchinson SJ, Goldberg D. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med. 2011;61:531\u201340.","journal-title":"Occup Med"},{"key":"1789_CR7","doi-asserted-by":"publisher","first-page":"e6336","DOI":"10.1097\/MD.0000000000006336","volume":"96","author":"Q Li","year":"2017","unstructured":"Li Q, Ren X, Lu C, Li W, Huang Y, Chen L. Evaluation of Apri and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT\u2264 2 ULN: a retrospective cohort study. Medicine. 2017;96:e6336.","journal-title":"Medicine"},{"key":"1789_CR8","doi-asserted-by":"publisher","first-page":"e0203312","DOI":"10.1371\/journal.pone.0203312","volume":"13","author":"KA Tufon","year":"2018","unstructured":"Tufon KA, Anong DN, Meriki HD, Georges TD, Maurice M, Kouanou YS, et al. Characterization and assessment of HBV chronically infected patients: identification of those eligible for treatment in the South West region of Cameroon. PLoS ONE. 2018;13:e0203312.","journal-title":"PLoS ONE"},{"key":"1789_CR9","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49:S45-55.","journal-title":"Hepatology"},{"key":"1789_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12929-015-0199-y","volume":"22","author":"JF Wu","year":"2015","unstructured":"Wu JF, Chang MH. Natural history of chronic hepatitis B virus infection from infancy to adult life: the mechanism of inflammation triggering and long-term impacts. J Biomed Sci. 2015;22:92.","journal-title":"J Biomed Sci"},{"key":"1789_CR11","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","volume":"63","author":"NA Terrault","year":"2016","unstructured":"Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver Diseases. A ASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63:261\u201383.","journal-title":"Hepatology"},{"key":"1789_CR12","first-page":"30","volume":"6","author":"N Fessehaye","year":"2018","unstructured":"Fessehaye N, Berhane A, Ahimed H. Prevalence of hepatitis B virus infection and associated seromarkers among pregnant women in Eritrea. J Hum Virol Retrovirol. 2018;6:30\u20138.","journal-title":"J Hum Virol Retrovirol"},{"issue":"67","key":"1789_CR13","first-page":"370","volume":"2017","author":"European Association for the Study of the Liver. European Association for the Study of the Liver. EASL","year":"2017","unstructured":"European Association for the Study of the Liver. European Association for the Study of the Liver. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;2017(67):370\u201398.","journal-title":"J Hepatol"},{"key":"1789_CR14","unstructured":"World Health Organization. Guidelines for the prevention care and treatment of persons with chronic hepatitis B infection: Mar15. World Health Organization; 2015."},{"key":"1789_CR15","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/j.vaccine.2011.12.116","volume":"30","author":"JJ Ott","year":"2012","unstructured":"Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212\u20139.","journal-title":"Vaccine"},{"key":"1789_CR16","first-page":"598","volume":"19","author":"S Baig","year":"2009","unstructured":"Baig S. Gender disparity in infections of hepatitis B virus. J Coll Phys Surg Pak. 2009;19:598\u2013600.","journal-title":"J Coll Phys Surg Pak"},{"key":"1789_CR17","doi-asserted-by":"publisher","first-page":"6252","DOI":"10.3748\/wjg.v20.i20.6252","volume":"20","author":"WC Liu","year":"2014","unstructured":"Liu WC, Liu QY. Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma. World J Gastroenterol. 2014;20:6252\u201361.","journal-title":"World J Gastroenterol"},{"key":"1789_CR18","first-page":"249","volume":"14","author":"J Poorolajal","year":"2009","unstructured":"Poorolajal J, Majdzadeh R. Prevalence of chronic hepatitis B infection in Iran: a review article. J Res Med Sci. 2009;14:249\u201358.","journal-title":"J Res Med Sci"},{"key":"1789_CR19","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3748\/wjg.v13.i14.2104","volume":"13","author":"J Shao","year":"2007","unstructured":"Shao J, Wei L, Wang H, Sun Y, Zhang LF, Li J, Dong JQ. Relationship between hepatitis B virus DNA levels and liver histology in patients with chronic hepatitis B. World J Gastroenterol. 2007;13:2104\u20137.","journal-title":"World J Gastroenterol"},{"key":"1789_CR20","first-page":"53","volume":"22","author":"R Roos","year":"2015","unstructured":"Roos R, Sonderup M, Smuts H, Gogela N, Setshedi M, Hairwadzi H, et al. A cross sectional study of HBeAg negative chronic hepatitis B virus infection in Cape Town, South Africa: P067. J Viral Hepat. 2015;22:53\u20134.","journal-title":"J Viral Hepat"},{"key":"1789_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.510310330","volume":"31","author":"HL Chan","year":"2000","unstructured":"Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen\u2013negative chronic hepatitis B in Hong Kong. Hepatology. 2000;31:763\u20138.","journal-title":"Hepatology"},{"key":"1789_CR22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1055\/s-2003-37590","volume":"23","author":"G Fattovich","year":"2003","unstructured":"Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23:47\u201358.","journal-title":"Semin Liver Dis"},{"key":"1789_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1365-2893.2002.00304.x","volume":"9","author":"ML Funk","year":"2002","unstructured":"Funk ML, Rosenberg DM, Lok AS. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9:52\u201361.","journal-title":"J Viral Hepat"},{"key":"1789_CR24","first-page":"103","volume":"11","author":"Y Yilmaz","year":"2011","unstructured":"Yilmaz Y, Yonal O, Kurt R, Bayrak M, Aktas B, Ozdogan O. Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): usefulness in patients with chronic liver disease: apri in chronic liver disease. Hepat Mon. 2011;11:103\u20136.","journal-title":"Hepat Mon"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-021-01789-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-021-01789-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T04:06:55Z","timestamp":1626840415000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-021-01789-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1789"],"URL":"https:\/\/doi.org\/10.1186\/s12876-021-01789-3","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of the Orotta College of Medicine and Health Sciences and the health facility management division of the Ministry of Health. All patients provided written informed consent to participate in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}